Market Overview

Depomed Reports First Quarter 2016 Financial Results


- First Quarter Revenues of $105M, up 225% over 1Q 2015 -
- NUCYNTA® Franchise First Quarter 2016 Net Sales of $69 million, up 53% over 1Q 2015 -
- Early Payment of $100M of Secured Debt Facility Demonstrates Commitment to Deleveraging -
- Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below -

NEWARK, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended March 31, 2016.

"Our NUCYNTA franchise continues to demonstrate strong growth with quarter-over-quarter revenue growth and year-over-year revenue growth of 53%. The most recent rolling 4-week NUCYNTA ER prescriptions are up 24% over the same period last year, continuing the acceleration we have demonstrated since relaunching the drug. NUCYNTA IR trends are also positive, with prescription counts in 4 of the last 5 months ahead of the same month in 2015," said Jim Schoeneck, President and CEO of Depomed. "The rest of our product portfolio continued to grow as well, with a combined $35 million in revenue, up 11% over the same quarter last year." 

Continued Mr. Schoeneck: "Moreover, in early April, we reduced our secured debt to $475 million with the early payment of $100 million, underscoring our commitment to deleveraging the Company and strengthening our balance sheet. Revenue during the first quarter of each year is historically lower than the prior quarter due to the reset of patient insurance plan deductibles and changes in wholesaler inventory levels.  Overall, we believe we are well-positioned to accelerate the growth of our NUCYNTA franchise, to continue to advance the rest of our portfolio during the remainder of 2016 and to continue to create value for our shareholders."

Business and Financial Highlights

  • First quarter 2016 revenues were $105 million, compared to $32 million for first quarter of 2015, a 225% increase
  • Record quarterly NUCYNTA® franchise revenue $69 million, up 53% over revenue recorded by Janssen in first quarter 2015
  • Quarterly non-GAAP adjusted earnings of $8 million, or $0.12 per share
  • Quarterly non-GAAP adjusted EBITDA of $27 million
  • Favorable IPR appeal ruling upheld validity of Depomed patents asserted against Purdue Pharma in patent infringement case
  • Secured debt balance reduced to $475 million with early payment of $100 million on April 4th, reinforcing commitment to deleveraging
  • Analyst and Investor Day provided update to company's business and marketing plans

NUCYNTA Franchise Highlights


  • First quarter 2016 net sales of $69 million
  • Net sales of $259 million since acquisition on April 2, 2015
  • NUCYNTA ER record all-time high prescription volume of approximately 28,800 reached in March1
  • NUCYNTA ER March year-over-year prescription growth of 23%1

Product Portfolio Highlights

  • Gralise® first quarter 2016 net sales were $19 million, an increase of 10% compared to $17.3 million in the same period last year. Total prescriptions were up over 70,000, an increase of 1% compared to the same period last year1
  • Cambia® first quarter 2016 net sales were $6.2 million, an increase of 15% compared to $5.4 million in the same period last year. Total prescriptions were over 30,000, an increase of 18% compared to the same period last year1
  • Lazanda® first quarter 2016 net sales of $4.6 million, an increase of 43% compared to $3.2 million in the same period last year. Total bottles prescribed for the first quarter 2016 were over 13,000, an increase of 35% over the same period in 20151

Source: SHA IDV

(in thousands, unaudited)
 Three Months Ended  
 March 31, 
 2016 2015 
Product sales, net:      
Nucynta products (note A)$69,364 $- 
Gralise 19,023  17,274 
Cambia 6,172  5,365 
Lazanda 4,560  3,186 
Zipsor 5,452  5,845 
Total product sales, net 104,571  31,670 
Royalties$209 $533 
Total revenues (GAAP Basis)$104,780  $32,203  
(A) Nucynta acquisition closed in April 2015

Revised 2016 Financial Outlook

Depomed is revising its 2016 financial guidance for total revenue, total non-GAAP SG&A expense and total non-GAAP R&D expense:

 Updated GuidancePrior Guidance
Total Revenue$490 to $520 million$485 to $525 million
Total Non-GAAP SG&A Expense$185 to $195 million$180 to $195 million
Total Non-GAAP R&D Expense$28 to $35 million$30 - $40 million

In March, Depomed hosted an Analyst and Investor Day in New York City during which management provided a business overview as well as a review of its marketed and development-stage product pipeline. An audio replay of the webcast including the presentation slides can be found on the Investor Relations page of Depomed's website at

Non-GAAP Financial Measures

In this press release, Depomed includes information about non-GAAP adjusted earnings, non-GAAP adjusted earnings per share and non-GAAP adjusted EBITDA, non-GAAP financial measures, as useful operating metrics for the three month periods ended March 31, 2016 and 2015 and its full year 2016 financial outlook. The Company believes that the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provides supplementary information to investors. The Company uses these non-GAAP financial measures in connection with its own planning and forecasting purposes and for measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP adjusted earnings and non-GAAP adjusted earnings per share are not based on any standardized methodology prescribed by GAAP and represent GAAP net income (loss) and GAAP earnings (loss) per share adjusted to exclude (1) amortization and non-cash adjustments related to product acquisitions, (2) stock-based compensation expense, (3) non-cash interest expense related to debt, (4) costs associated with the Company's defense against the Horizon Pharma hostile takeover bid, and to adjust (5) the income tax provision to reflect the estimated amounts payable or receivable in cash. Non-GAAP adjusted EBITDA is not based on any standardized methodology prescribed by GAAP and represents GAAP net income (loss) adjusted to exclude (1) amortization and non-cash adjustments related to product acquisitions, (2) stock-based compensation expense, (3) depreciation, (4) taxes, (5) costs associated with the Company's defense against the Horizon Pharma hostile takeover bid, (6) interest income and expense, and (7) transaction costs associated with product acquisitions. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

Conference Call

Depomed will host a conference call today, Thursday, May 5th, beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results. Participants can access the call by dialing (844) 839-0046 (United States) or (857) 270-6032 (International). The conference call will also be available via a live webcast under the Investor Relations section of Depomed's website at Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of NUCYNTA ER, NUCYNTA, Gralise, CAMBIA, Zipsor and Lazanda, Depomed's financial outlook for 2016 and expectations regarding financial results and potential business opportunities and other risks detailed in the company's Securities and Exchange Commission filings, including the company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

(in thousands, except per share amounts) 
  Three Months Ended   
  March 31,  
  2016 2015  
Product sales, net $ 104,571  $ 31,670   
Royalties   209    533   
Total revenues   104,780    32,203   
Costs and expenses:        
Cost of sales   23,549    3,112   
Research and development expense   5,949    1,858   
Selling, general and administrative expense   52,559    34,542   
Amortization of intangible assets   27,037    2,540   
Total costs and expenses   109,094    42,052   
Income from operations   (4,314)   (9,849)  
Interest and Other income   130    57   
Interest expense   (22,727)   (6,022)  
Benefit from (provision for) income taxes   5,994    4,181   
Net income (loss) $ (20,917) $ (11,633)  
Basic net income (loss) per share $ (0.34) $ (0.20)  
Diluted net income (loss) per share $ (0.34) $ (0.20)  
Shares used in calculating basic net income per share   60,898,186    59,560,873   
Shares used in calculating diluted net income per share   60,898,186    59,560,873   

(in thousands)  
  March 31, December 31, 
  2016 2015 
Cash, cash equivalents and marketable securities $194,334 $209,768 
Accounts receivable  70,750  71,687 
Inventories  10,854  10,494 
Income taxes receivable  6,362  6,358 
Property and equipment, net  15,075  14,794 
Intangible assets, net  981,957  1,008,994 
Deferred tax assets  42,584  22,995 
Prepaid and other assets  13,716  12,159 
Total assets $1,335,632 $1,357,249 
Accounts payable $7,371 $12,805 
Income taxes payable  12,996  - 
Interest payable  16,344  18,672 
Accrued liabilities  46,111  62,931 
Accrued rebates, returns and discounts  122,033  121,058 
Senior notes  563,530  563,012 
Convertible notes  241,032  237,313 
Contingent consideration liability  14,864  14,971 
Other liabilities  11,612  11,432 
Shareholders' equity  299,739  315,055 
Total liabilities and shareholders' equity $1,335,632 $1,357,249 

(in thousands, except per share amounts) 
 Three Months Ended  
  March 31,   
 2016 2015  
GAAP net income (loss)$ (20,917) $ (11,633)  
Non-cash interest expense on debt  4,235    3,421   
Intangible amortization related to product acquisitions  27,037    2,540   
Inventory step-up related to product acquisitions  10    145   
Contingent consideration related to product acquisitions  417    (1,099)  
Stock based compensation  3,910    2,813   
Non-cash income tax adjustment  (7,014)   (4,181)  
Horizon defense costs  185    -   
Non-GAAP adjusted earnings$ 7,863  $ (7,994)  
Add interest expense of convertible debt, net of tax (1)  1,908    -   
Numerator$ 9,771  $ (7,994)  
Shares used in calculation (1)  80,693    59,561   
Non-GAAP adjusted earnings per share (1)$ 0.12  $ (0.13)  
(1) The Company uses the if-converted method to compute diluted earnings per share with respect to its convertible debt.  There was no add-back of interest expense or additional dilutive shares related to the convertible debt for the three months ended March 31, 2015, as the effect is anti-dilutive. 

(in thousands)
 Three Months Ended 
  March 31,  
 2016 2015 
GAAP net income (loss)$ (20,917) $ (11,633) 
Intangible amortization related to product acquisitions  27,037    2,540  
Inventory step-up related to product acquisitions  10    145  
Contingent consideration related to product acquisitions  417    (1,099) 
Stock based compensation  3,910    2,813  
Interest income (other)  (130)   (57) 
Interest expense  22,133    5,577  
Depreciation  631    420  
Provision (benefit) from income taxes  (5,994)   (4,181) 
Horizon defense costs  185    -  
Transaction costs  43    2,459  
Non-GAAP adjusted EBITDA$ 27,325  $ (3,016) 

(in thousands) 
  Three Months Ended  Three Months Ended  
  March 31, 2016 March 31, 2015 
  Reported Adjustments Adjusted Reported Adjustments Adjusted 
Total revenues   104,780    -    104,780    32,203    -    32,203  
Cost of sales   23,549    (18)(a)  23,531    3,112    (145)(a) 2,967  
Research and development expense   5,949    (77)(b)  5,872    1,858    (137)(b) 1,721  
Selling, general and administrative expense   52,559    (3,833)(c)  48,726    34,542    (1,132)(c) 33,410  
Amortization of intangible assets   27,037    (27,037)(d)  -    2,540    (2,540)(d) -  
Interest expense   (22,727)   (4,829)(e)  (17,898)   (6,022)   (3,866)(e) (2,156) 
Benefit from (provision for) income taxes   5,994    (7,014)(f)  (1,020)   4,181    (4,181)(f)  -  
Net income/adjusted earnings   (20,917)   28,780 (g)  7,863    (11,633)   3,639 (g) (7,994) 
Explanation of adjustments:                   
(a) Inventory step-up related to product acquisitions and stock based compensation 
(b) Stock-based compensation 
(c) Horizon defense costs of $185 and $0, stock-based compensation of $3,825 and $2,675, contingent consideration of $(177) and $(1,543), for the three months ended in March 31, 2016 and 2015, respectively 
(d) Amortization of intangible assets 
(e) Non-cash interest expense of $4,235 and $3,421, and contingent consideration expense of $594 and $445, for three months ended March 31, 2016 and 2015, respectively 
(f) Non-cash taxes 
(g) Calculated by taking (f) minus sum of (a) through (e) 

INVESTOR CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications Depomed, Inc. 510-744-8000

Primary Logo

View Comments and Join the Discussion!